Biosimilar tracker
Ordinary pills have generics — exact chemical copies. But biologics (drugs grown in living cells, like Humira or Enbrel) are too complex to copy exactly. Their competitors are biosimilars: not identical, but proven to work the same with no clinically meaningful difference. A few go a step further and are rated interchangeable, meaning a pharmacist can swap them for the brand without calling the doctor. Below is every reference biologic that now has competition.
Source and freshness: everything on this page is digested monthly from the FDA's Purple Book — the official registry of licensed biologics and the only FDA source that still records interchangeability product by product — last refreshed from FDA data on September 3, 2026.
ⓘ How this was built
- FDA Purple Book (licensed biologics and biosimilars)
Reference biologics and their biosimilar/interchangeable competitors exactly as licensed in FDA's Purple Book, refreshed monthly. No modeling.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Reference biologics and their biosimilar competition
Expand a brand to see each biosimilar, who makes it, and when it was approved. More competitors usually means bigger price cuts.
Note: a brand with more biosimilars (adalimumab/Humira has the most) faces the most competition — though whether patients actually see lower prices also depends on rebates and formulary choices. See the biosimilars explainer.
Source: FDA Purple Book database of licensed biological products — 351(a) reference products matched to their 351(k) biosimilar and interchangeable competitors. Educational only — not clinical or purchasing advice.